Type I IFN-neutralizing auto-Abs in the study population
| Characteristic . | auto-Ab+, n = 82a . | No auto-Ab, n = 236a . |
|---|---|---|
| Age (years) | 69.52 [15.27] | 60.88 [15.32] |
| ≤40 | 3/29 (10%) | 26/29 (90%) |
| 41–65 | 20/137 (15%) | 117/137 (85%) |
| >65 | 57/148 (39%) | 91/148 (61%) |
| Unknown | 0/4 (0%) | 4/4 (100%) |
| Sex | | |
| F | 19/107 (18%) | 88/107 (82%) |
| M | 62/207 (30%) | 145/207 (70%) |
| Unknown | 1/4 (25%) | 3/4 (75%) |
| WNV groups | | |
| WNVD | 81/225 (36%) | 144/225 (64%) |
| WNVF | 1/61 (2%) | 60/61 (98%) |
| WNVIC | 1/32 (3%) | 31/32 (97%) |
| Subgroups of WNVD | | |
| Non-neuroinvasive WNVD | 9/25 (36%) | 16/25 (64%) |
| Neuroinvasive WNVD | | |
| -All | 71/200 (36%) | 129/200 (64%) |
| -WNE | 59/154 (38%) | 95/154 (62%) |
| -WNM | 8/32 (25%) | 24/32 (75%) |
| -AFP | 2/7 (29%) | 5/7 (71%) |
| -UNS | 2/7 (29%) | 5/7 (71%) |
| Characteristic . | auto-Ab+, n = 82a . | No auto-Ab, n = 236a . |
|---|---|---|
| Age (years) | 69.52 [15.27] | 60.88 [15.32] |
| ≤40 | 3/29 (10%) | 26/29 (90%) |
| 41–65 | 20/137 (15%) | 117/137 (85%) |
| >65 | 57/148 (39%) | 91/148 (61%) |
| Unknown | 0/4 (0%) | 4/4 (100%) |
| Sex | | |
| F | 19/107 (18%) | 88/107 (82%) |
| M | 62/207 (30%) | 145/207 (70%) |
| Unknown | 1/4 (25%) | 3/4 (75%) |
| WNV groups | | |
| WNVD | 81/225 (36%) | 144/225 (64%) |
| WNVF | 1/61 (2%) | 60/61 (98%) |
| WNVIC | 1/32 (3%) | 31/32 (97%) |
| Subgroups of WNVD | | |
| Non-neuroinvasive WNVD | 9/25 (36%) | 16/25 (64%) |
| Neuroinvasive WNVD | | |
| -All | 71/200 (36%) | 129/200 (64%) |
| -WNE | 59/154 (38%) | 95/154 (62%) |
| -WNM | 8/32 (25%) | 24/32 (75%) |
| -AFP | 2/7 (29%) | 5/7 (71%) |
| -UNS | 2/7 (29%) | 5/7 (71%) |
aMean [SD], counts, or frequency (%). WNE, WNV encephalitis; WNM, WNV meningitis; AFP, acute flaccid paralysis; UNS, unspecified neurological syndrome.
The round and square brackets indicate that individuals with ages at the extremes of the range are excluded (40 year-old individuals) or included (65-year-old individuals) in this age group.